<SEC-DOCUMENT>0001193125-25-303047.txt : 20251201
<SEC-HEADER>0001193125-25-303047.hdr.sgml : 20251201
<ACCEPTANCE-DATETIME>20251201062030
ACCESSION NUMBER:		0001193125-25-303047
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20251201
DATE AS OF CHANGE:		20251201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268603
		FILM NUMBER:		251537078

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d24956d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PROSPECTUS SUPPLEMENT NO. 13 <BR>(to Prospectus dated May&nbsp;13, 2025)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-268603</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PROSPECTUS SUPPLEMENT NO. 13 <BR>(to Prospectus dated May&nbsp;13, 2025)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-280882</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PROSPECTUS SUPPLEMENT NO. 13 <BR>(to Prospectus dated May&nbsp;13, 2025)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-275117</FONT></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 1,594,207 Shares of Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 198,810 Shares of Common Stock Issuable Upon the Exercise of Warrants </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 1,402,955 Warrants </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 3,593,288 Shares of Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 3,250,000 Shares of Common Stock offered by the Selling Securityholder </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 6,685,714 Shares of Common Stock </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:9pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and supplements: (i)&nbsp;the prospectus dated May&nbsp;13, 2025, which forms a part of our registration
statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (No. <FONT STYLE="white-space:nowrap">333-268603)</FONT> for which Post-Effective Amendment No.&nbsp;3 was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on
May&nbsp;7, 2025 and declared effective by the SEC on May&nbsp;13, 2025 (the &#8220;Post-deSPAC Prospectus&#8221;); (ii) the prospectus dated May&nbsp;13, 2025, which forms a part of our registration statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> (No. <FONT STYLE="white-space:nowrap">333-280882)</FONT> for which Post-Effective Amendment No.&nbsp;1 was filed with the SEC on May&nbsp;7, 2025 and declared effective by the SEC on May&nbsp;13, 2025 (the
&#8220;Conversion Prospectus&#8221;); and (iii)&nbsp;the prospectus dated May&nbsp;13, 2025, which forms a part of our registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (No.
<FONT STYLE="white-space:nowrap">333-275117)</FONT> for which Post-Effective Amendment No.&nbsp;2 was filed with the SEC on May&nbsp;7, 2025 and declared effective by the SEC on May&nbsp;13, 2025 (the &#8220;Oramed Resale Prospectus&#8221; and
together with the Post-deSPAC Prospectus and the Conversion Prospectus, the &#8220;Prospectuses&#8221;). This prospectus supplement is being filed to update and supplement the information in the Prospectuses with the information contained in our
Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on November&nbsp;28, 2025 (the &#8220;Current Report&#8221;). Accordingly, we have attached the Current Report to this prospectus supplement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;SCLX&#8221;. On November&nbsp;28, 2025, the last reported sales
price per share of our Common Stock was $20.36. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol &#8220;SCLXW.&#8221; On November&nbsp;28, 2025, the closing sale price per warrant of our Public Warrants was $0.22. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;15, 2025, we effected a reverse stock split of our Common Stock at a ratio of <FONT STYLE="white-space:nowrap">1-for-35</FONT>
(the &#8220;Reverse Stock Split&#8221;). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect of the Reverse Stock Split. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and supplements the information in the Prospectuses and is not complete without, and may not be delivered or
utilized except in combination with, the Prospectuses, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectuses and if there is any inconsistency between the information in the
Prospectuses and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:9pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>See the section titled &#8220;Risk Factors&#8221; beginning on page 23 of the Post-deSPAC Prospectus, page 23 of the Conversion Prospectus,
and page 23 of the Oramed Resale Prospectus, as well as risks and uncertainties described under similar headings in any amendments or supplements to the Prospectuses to read about factors you should consider before buying our securities. </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:9pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the accuracy or adequacy of this prospectus supplement or the Prospectuses. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is&nbsp;December&nbsp;1, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">8-K</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): November&nbsp;25, 2025 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-39852</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>92-1062542</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction<BR>of incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>960 San Antonio Road, Palo Alto, California, 94303 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#8217;s telephone number, including area code: (650) <FONT STYLE="white-space:nowrap">516-4310</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading<BR>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange<BR>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Common stock, par value $0.0001 per share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SCLX</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The Nasdaq Stock Market LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Warrants to purchase common stock at an exercise price of $402.50 per share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SCLXW</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The Nasdaq Stock Market LLC</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.
&#8194;&#9746; </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;2.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Completion of Acquisition or Disposition of Assets </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Datavault Acquisition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed, on
September&nbsp;25, 2025, Scilex Holding Company (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement (the &#8220;Datavault SPA&#8221;) with Datavault AI Inc., a Delaware corporation (&#8220;Datavault&#8221;), pursuant to which
Datavault agreed to issue and sell, and the Company agreed to purchase, 15.0&nbsp;million shares (the &#8220;Datavault Shares&#8221;) of common stock of Datavault (&#8220;Datavault Common Stock&#8221;) in the initial closing which occurred on
September&nbsp;26, 2025 (the &#8220;Initial Closing&#8221;) and a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant (the <FONT STYLE="white-space:nowrap">&#8220;Pre-Funded</FONT> Warrant&#8221;) to purchase 263,914,094 shares of Datavault
Common Stock in a subsequent closing (the &#8220;Subsequent Closing&#8221;), for an aggregate purchase price of $150&nbsp;million in Bitcoin (&#8220;BTC&#8221;) (based on the spot exchange rate for BTC as published by Coinbase.com at 8:00 p.m. (New
York City time) on the trading day immediately prior to the date of the Initial Closing Date, or September&nbsp;25, 2025 (such rate, the &#8220;Spot Exchange Rate&#8221;)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Datavault SPA, the Subsequent Closing was subject to the satisfaction of the condition that the stockholders of Datavault approve the issuance
of the shares of Datavault Common Stock underlying the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant. On November&nbsp;24, 2025, Datavault obtained such stockholder approval at its annual meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;25, 2025, the Subsequent Closing was consummated with the Company transferring an amount of BTC (based on the Spot Exchange Rate) in
satisfaction of the payment of the remainder of the aggregate purchase price to Datavault and Datavault issuing the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;25, 2025, following the Subsequent Closing, the Company exercised the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant in full for
an aggregate exercise price of approximately $26.4&nbsp;thousand, paid in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Initial Closing, the Company and Datavault entered into a
license agreement providing for the use by the Company of certain intellectual property owned by Datavault. Other than the preceding sentence and the transactions consummated pursuant to the Datavault SPA, there are no material relationships between
the Company and Datavault. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing summary of the Datavault SPA does not purport to be complete and is qualified in its entirety by reference to
the full text of the Datavault SPA, a copy of which is filed herewith as Exhibit 10.1 and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;7.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;26, 2025, the Company issued a press release announcing the Subsequent Closing under the Datavault SPA. A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
information in Item 7.01 of this Current Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;8-K&nbsp;(including&nbsp;Exhibit</FONT> 99.1 attached hereto) is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing by the Company, under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1<SUP STYLE="font-size:75%; vertical-align:top">#</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Securities Purchase Agreement, dated September&nbsp;25, 2025, by and between Scilex Holding Company and Datavault AI Inc. (incorporated by reference to Exhibit&nbsp;10.1 of the Company&#8217;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed on September&nbsp;26, 2025).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated November&nbsp;26, 2025.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> Item 601. The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. </P></TD></TR></TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SCILEX HOLDING COMPANY</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Henry Ji, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Henry Ji, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer&nbsp;&amp; President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: December 1, 2025 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2">


<IMG SRC="g26514g1129020453751.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>&#8195;&#8195;FOR IMMEDIATE RELEASE</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><B>&#8195;&#8195;November&nbsp;26, 2025</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing
Its <FONT STYLE="white-space:nowrap">Two-Tranche</FONT> Equity Financing in Datavault AI Inc. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Scilex closed the second tranche, purchasing a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant
exercisable for 263,914,094 shares of Datavault AI Inc. (Nasdaq: DVLT; &#8220;Datavault AI&#8221;) common stock in Bitcoin (BTC) (based on the spot exchange rate of BTC as of the signing of the strategic investment). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The closing followed the approval by the Datavault AI stockholders, obtained at Datavault AI&#8217;s
November&nbsp;24, 2025 annual meeting, of the issuance of the shares of Datavault common stock upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Scilex has exercised the warrant in full and the shares of Datavault AI common stock issued upon such exercise
have an approximate value of $583.3&nbsp;million based on the closing price of $2.21 per share of Datavault AI common stock on the Nasdaq Capital Market on November&nbsp;25, 2025. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Both companies will ramp up collaboration to deliver growth in Real World Asset tokenization in 2026 and beyond.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PALO ALTO, CALIFORNIA &#8211; November</B><B></B><B>&nbsp;26, 2025 (GLOBE NEWSWIRE)&#8212;</B>Scilex Holding Company
(&#8220;Scilex&#8221; or the &#8220;Company&#8221;) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain management products for the
treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that it has closed the second tranche of its strategic investment in Datavault AI in BTC (based on the spot exchange rate of BTC as of the signing
of the strategic investment). The closing of this second tranche followed the approval by the Datavault stockholders at Datavault&#8217;s November&nbsp;24, 2025 annual meeting of the issuance of the shares of Datavault common stock upon exercise of
the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. Scilex&#8217;s shares of Datavault common stock issued upon the exercise in full of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant has an approximate value of
$583.3&nbsp;million based on the closing price of $2.21 per share of Datavault AI common stock on the Nasdaq Capital Market on November&nbsp;25, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on Scilex Holding Company, refer to www.scilexholding.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on ZTlido<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> including Full Prescribing Information, refer to www.ztlido.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, including Full Prescribing Information, refer to www.elyxyb.com.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on Gloperba<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, including Full Prescribing Information, refer to
www.gloperba.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g26514g1129020453845.jpg" ALT="LOGO">
&#8195;


<IMG SRC="g26514g1129020453938.jpg" ALT="LOGO">
<B>&#8195;</B>


<IMG SRC="g26514g1129020454032.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Scilex Holding Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain
management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with
<FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex&#8217;s commercial products include: (i)&nbsp;ZTlido<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for the relief of neuropathic pain associated
with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii)&nbsp;ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a potential first-line treatment and the only <FONT STYLE="white-space:nowrap">FDA-approved,</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-use</FONT></FONT> oral solution for the acute treatment of migraine, with or without aura, in adults; and
(iii)&nbsp;Gloperba<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Scilex has three product candidates: <FONT STYLE="white-space:nowrap">(i)&nbsp;SP-102</FONT> (10 mg, dexamethasone sodium phosphate viscous gel)
(&#8220;SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&#8221; or <FONT STYLE="white-space:nowrap">&#8220;SP-102&#8221;),</FONT> which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel
formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) <FONT
STYLE="white-space:nowrap">SP-103</FONT> (lidocaine topical system) 5.4%, <FONT STYLE="white-space:nowrap">(&#8220;SP-103&#8221;),</FONT> a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex
has recently completed a Phase 2 trial in acute low back pain. <FONT STYLE="white-space:nowrap">SP-103</FONT> has been granted Fast Track status from the FDA in low back pain; and <FONT STYLE="white-space:nowrap">(iii)&nbsp;SP-104</FONT> (4.5 mg, <FONT
STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules) <FONT STYLE="white-space:nowrap">(&#8220;SP-104&#8221;),</FONT> a novel <FONT STYLE="white-space:nowrap">low-dose</FONT> delayed-release naltrexone
hydrochloride being developed for the treatment of fibromyalgia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex is headquartered in Palo Alto, California. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Datavault AI Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Datavault AI<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets. Datavault AI&#8217;s cloud-based platform provides comprehensive solutions with a
collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI&#8217;s Acoustic Science Division features WiSA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,
ADIO<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and Sumerian<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission
technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of high-performance computing to provide solutions for experiential data perception, valuation and
secure monetization. Datavault AI&#8217;s cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports&nbsp;&amp; entertainment, events&nbsp;&amp; venues, biotech, education, fintech,
real estate, healthcare, energy and more. The Information Data Exchange<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world
objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI&#8217;s technology suite is completely customizable and offers AI and Machine Learning (ML)&nbsp;automation, third-party integration, detailed analytics and
data, marketing automation and advertising monitoring. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Datavault AI is headquartered in Beaverton, OR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Learn more about Datavault AI at www.dvlt.ai </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes
forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as &#8220;believe,&#8221;
&#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221;
&#8220;potential,&#8221; &#8220;seem,&#8221; &#8220;seek,&#8221; &#8220;future,&#8221; &#8220;outlook&#8221; or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to,
statements regarding future events, future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product
candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements
regarding <FONT STYLE="white-space:nowrap">SP-102,</FONT> if approved by the FDA, Scilex&#8217;s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements
are based on management&#8217;s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any
investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are
beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex&#8217;s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, market and
other conditions, general economic, political and business conditions; the ability of Scilex and its subsidiaries to achieve the benefits of the strategic investment in and other transactions with Datavault, including future financial and operating
results; risks related to the outcome of any legal proceedings that may be instituted against the parties regarding the strategic investment or other transactions between the parties; the risk that the strategic investment or other transactions
between the parties disrupt current plans and operations; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key
employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the
regulatory pathway for Scilex&#8217;s product candidates; the risk that Scilex&#8217;s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient
population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of
failure to realize the anticipated benefits of the transactions contemplated with Datavault and other risks and uncertainties </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indicated from time to time and other risks set forth in Scilex&#8217;s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes
are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex&#8217;s expectations, plans or forecasts of future events and views as of
the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex
specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex&#8217;s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned
not to place undue reliance on these forward-looking statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and Media </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">960 San Antonio Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94303 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office: (650) <FONT STYLE="white-space:nowrap">516-4310</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: investorrelations@scilexholding.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Website:
www.scilexholding.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEMDEXA<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> <FONT STYLE="white-space:nowrap">(SP-102)</FONT> is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA
is planned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZTlido<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark owned by Scilex Pharmaceuticals Inc., a
wholly-owned subsidiary of Scilex Holding Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gloperba<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is the subject of an exclusive,
transferable license to use the registered trademark by Scilex Holding Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a
registered trademark owned by Scilex Holding Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Bio<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> is a trademark owned by
Scilex Holding Company, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All other trademarks are the property of their respective owners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:75%; vertical-align:top">&copy;</SUP> 2025 Scilex Holding Company All Rights Reserved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page | 4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g26514g1129020453751.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g26514g1129020453751.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% 1H# 2(  A$! Q$!_\0
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M.EM?7SG&=L<:_>D;T%<)"/'?C>/[7'=+HFF2<Q*K%7<>N1\Q^N0/2LK7Y_\
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MNN\5?\DUN?\ KUC_ )K7(_&#_D(Z7_UR?^8KK_%7_)-;G_KUC_FM &/\(?\
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MQ_VOY_7KZ'7FGC_P,TI?7-'0K<)\\\*<%N^]??U'X]>H!Z4S*BEF("@9))X
MKR#QCXNNO%%^N@:"'DMF?8S)UG;_ .)'_P!>LF\\;Z[XATBUT)%+32'RY'C^
M_<>@/I[^M>D^"O!D/AFS\^<+)J4J_O).H0?W5_J>] %?2/!K>'/"MZ+/$FM3
M6[ S+U#8X5#V^O<_IC6T(>]1=/.)/.!LX8P?,AQ(N?-'50$#9SUR0<G%>G48
MYS0 4444 >0^*+N/Q=KVIZ0H07UA(?L!'!E"C$D9]3D%A]"*Y'2KZZTJ^2>W
MD:&>,]1U'L:O^';3^T?BOY4F<+?RRMS_ '69OYBO1O%_@*/6)&U#3=D-\>70
M\++_ (-[]_UKS73E43FMTSZJEBJ.%E&A4^%K[O\ @,M>'?'-EJJ)!>LMM>=.
M3A'/L>WT-=;7SQ<P76FW#6U[!)!,O57&#75>#?$6K'5[73HKHO;LWSI+\P5!
MRV/3@&KI8IWY9HQQN3TW%UL/*RWMT^3(OB!*K^*[D _<5%/_ 'R#_6N@^%,9
M^PZE-V:5%'X G^M>?>(M5&I:W>72GY9)6*_[N>/TQ7667BR'P'X<L[-K,W%]
M=(;IUW[0@;[N>#SM XK.E)>V<WL=6-IS^HPP\%>327W;GJ%[>6^G64UY=2".
M"%"[N>P%>>_"WS-1U#Q#KSH52\N $!^K,1^&Y:X^74?$_P 3=32Q3]W9JV65
M 1%$/[S'N?\ (KVC0M&MM T>WTVT!\N%>6(Y=N['W)KKC+VLU);(\.K26%HN
MG)WG*WR11U;Q1X?L[XZ1J<RB63:#%)"S*0W3)QC%1S> _#$S[FTF($_W'91^
M0.*ROB#X,D\0P1WU@!]O@7:4)QYJ=<9]1SCZUR>F_$77?#J+IVKV!G,0VCSL
MQR #U..?R_&N@\T[W_A7GA;_ *!8_P"_TG_Q507/PU\,7$3(EF\#$</',V1^
M9(K!_P"%PVNW_D#S9]/.'^%9>H?%'6=4!M=(T\6\DG 9<RR?AP.?P- %3P69
M]!^)+:5%,9(6DDMY,='"AB#CUR/YU)XQQIOQ4@NY?EC,L$V3_=& 3_XZ:Z'X
M>^"KO3;MM:U=2ETP(BB8Y9<]6;W]O<YK5\>^#V\2V4=Q9[1?VX(0$X$B_P!W
M/KZ?CZTP.QSD9%%>-:;X_P!?\,(NFZMIYG$(VJ)LI( .V>X_#\:V1\8;7;SH
M\V?3SA_A2 ],KE(O'NG3^)_["AM[B2?SC#YB[=F1U/7.!@UQ>H?$_6=75K/1
M].^SR2?*&0F23\.!@_A6[\/O!-QI$S:OJJ[;QU(BB)R8P>I/N>GY_@ 8_P 8
M/^0CI?\ UR?^8KK_ !5_R36Y_P"O6/\ FM<A\8.=1TO'_/)_YBN[U33I-6\#
MR6,.#++9J$!/5@ 0/S% '-_"#_D7;[_K[/\ Z M>AUX7X:\8WO@J&ZTZ72_,
M9I=[+(Q1E. ,=#Z"MW_A<-Q_T!(__ @__$T >KUR/Q,_Y$:\_P!^/_T,5RW_
M  N&X_Z D?\ X$'_ .)K?NKBX\=_#>ZEBM1%<2$E(5;=DHP.,\<G% '/^!/!
M.BZ]X<^VWT4K3><R960@8 '^-=-_PJ_PS_SPN/\ O\:X'PUX\N_"FG/ICZ6)
M2LI?YW*,I.,@C!]*V?\ A<-Q_P! 2/\ \"#_ /$TP.E_X5?X9_YX7'_?XUKZ
M#X5TOPX\[Z='(IF #[W+=,X_G7!_\+AN/^@)'_X$'_XFM;PU\29M?UZWTU]+
M2!9MW[P3%L84GICVI >@UY5X[\;2W]P?#^A,TF]O+FEBY,AZ;%QV]3W^G6;Q
M[XY=W?0M$<O(Y\N>>/DDGC8N._8G\*U_ ?@=-!A74-00-J4B\*>1"#V_WO4_
MA]0#C-2^'&J:/H4&JV\S/>1?O)XH^L8Z@J1UQW_2NU\">-TU^!;"^<)J4:]3
MP)@.X]_4?C].VKRCQUX+ETRX/B#0@T:HWF31Q<&(_P!]?;U]/IT /5Z*X_P1
MXUB\1VHM;LK'J<2_,O02C^\O]1784 %%%% 'C%W$/!_QCBO+CY+*[F:19#TQ
M("#^3$_A7L]8GB?PQ8^*=,^R78*.AW0S*/FC;^H]17$Q:CXY\$P_8[G3O[9L
M(AB*:/)8+V&1DC\1^-<Z_=-WV9Z,[8N$6G::5K/KZ'HNHZ58:M!Y-_:QSIVW
M#D?0]1^%>7^*UT3P6+JVTF21M1O(O*96<,+>,_>]\D8'/:H-0^(7B_5U-KI>
MBRVC-P6CB:23\"1@?E4?A_X6ZMJ=R+SQ!*UM$S;F0ONFD^IYQ]3S[5G4DJCM
M!:]SJPU-X97Q$[1_EON9?@?PS-XFU=9)4/\ 9]NP:=ST;_8'N?T'X5Z))\-+
M#4-6FU+6+R>\EE?<8U'EH!V7C)P!@=>U==I^GVFEV4=G90+#!&,*B_S]S[U9
MK2GAXQC9ZG+B<RJU:CE!V6Q6L=/L],M5MK&VBMX5Z)&N!_\ 7-6:**Z-CSVV
MW=A44]K;W2;+B"*9?21 P_6L?Q!J4FG7>FL)72%Y2)0JYW#CM5:X\0+=:OID
M-E+,J/*1*K1E=PXQU'UH$:7_  C>A[MW]CV&?^O=/\*NV]G:V@Q;6T,(](XP
MO\JS-<U"YAN++3[-Q'<7C$>:1G8HQD@>O-5-2%_X?MAJ":C-=1*X$T4^#D$X
M^4]J .EHK$\2WLUKH)N;65HW++AAUP:VA]T?2@".>V@N4V7$,<J?W9$##]:H
M'PWH9;<='L,_]>Z?X5G9OK_Q)J%HFHS6\4"HR*@!Z@>M6])O;L:G=Z7>R+-)
M H=)@NTLIQU'KR* -.WL[6T7;;6T,*^D:!?Y5/6)I]Y<2^)M5MI)2T,(C,:'
MHN1S5.[UJ\L/$EP&5I=/C5/- ',>0/F'X_SH Z*:UM[@@SP12D="Z!L?G4@
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MV]TV\<2S6A&)@,;U/3(]>GYT :']F6'_ #XVW_?I?\*?'8VD+AXK6!''1EC
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M&P1JV_RS+M^79U\S\O\ /:NCCMRD2(T\KLJ@%B>6]Z )Z*** "BBB@ HHHH
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.WE>7M]\YSFM6BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g26514g1129020453845.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g26514g1129020453845.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? !\# 2(  A$! Q$!_\0
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BUGZ+I@T?2(+ 2^:(AC?MQG\*T*SKSYZDI7NKE4X\L4C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g26514g1129020453938.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g26514g1129020453938.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ; !L# 2(  A$! Q$!_\0
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MX;6'7]:O[E/M#\21W!.QCR 0.E>@>&/CM#%X;LH]84S:@B%99,XW8)P?KC%
M'"_#7_DN\?\ U]W/\GIGB0 _M 3 C/\ Q-!_.G_#7_DN\?\ U]W/\GIGB3_D
LX";_ +"@_G0!Z]^T!_R39_\ KYC_ )U\J5]5_'__ ))M)_U\Q_SKY4H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g26514g1129020454032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g26514g1129020454032.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  7 !\# 2(  A$! Q$!_\0
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M52.X- '2:3\))?#NH/=:'XFN+8XV0_:+.*X>"/).Q&?H.>V,]ZWO^$<\7_\
M0^2_^"JW_P *** #_A'/%_\ T/DO_@JM_P#"N=O?@Q;ZUJ;WFNZ]<W:RX,\5
3M;QVHF89VL^S@D9ZXS110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
